RecruitingPhase 3NCT06439082
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Sponsor: Novartis Pharmaceuticals
Louisville, KY · +16 more sites